Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021

Business Wire April 10, 2021

Clovis Oncology's Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

Business Wire March 19, 2021

Clovis Oncology Announces 2020 Operating Results

Business Wire February 23, 2021

Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23

Business Wire February 17, 2021

Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Business Wire February 11, 2021

Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Business Wire February 4, 2021

Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

Business Wire January 11, 2021

Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

Business Wire December 29, 2020

Clovis Oncology's Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Business Wire December 21, 2020

Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

Business Wire November 24, 2020

Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference

Business Wire November 20, 2020

Clovis Oncology Announces Third Quarter 2020 Operating Results

Business Wire November 5, 2020

Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes

Business Wire November 5, 2020

Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5

Business Wire October 20, 2020

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

Business Wire September 17, 2020

Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting

Business Wire September 10, 2020

Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

Business Wire September 9, 2020

Five Pharmaceutical Stocks Investors May Want to Keep an Eye On

Livemoney September 9, 2020

Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Business Wire September 8, 2020

FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Business Wire August 26, 2020